- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02769572
Moxibustion in Osteoarthritis of the Knee
The Effectiveness of Moxibustion Treatment for Osteoarthritis of the Knee : a Double-blinded, Double-dummy, Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aim: To evaluate the effectiveness of moxibustion treatment for patients with osteoarthritis of the knee, with respect to relieving pain, improving the dysfunction and improving their quality of life as well.
Design: A multicentre, double-blinded, double-dummy, randomized controlled clinical study will be performed in China. Eligible participants will be randomly assigned to moxibustion group (real moxibustion plus placebo gel) and the control group (diclofenac sodium gel plus sham moxibustion) with a 1:1 allocation ratio. Participants in both groups will receive 12 sessions of real/sham moxibustion in 4 weeks at 3 acupoints (ST35, EX-LE4, ST36 ). Either diclofenac sodium gel or placebo gel will be applied 4 g per knee 4 times daily for 4 weeks. The whole study period is 13 weeks, with a 1-week run-in period, 4-week treatment phase, and 8-week follow-up phase. The primary outcome measure will be the change of the global scale of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at the end of the course. The secondary outcomes include the change of other subscales (pain, stiffness, and function) of WOMAC, Visual Analogue scale (VAS) and Patient Global Assessment (PGA). Safety will be assessed at every visit.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610075
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, aged between 40 and 75 years, with knee osteoarthritis diagnosed according to American College of Rheumatology criteria
- Radiologic confirmation of osteoarthritis in 1 or both knees (Kellgren-Lawrence score 2 or 3)
- Had knee pain in one or both knee(s) of longer than 3 months'duration
- The average severity of knee pain at least 3 points on a10-point of visual analogue scale(VAS)
- Never experienced moxibustion before this trial
- Participants who are willing to comply with our study protocol
- Participants who agree to sign the consent form
Exclusion Criteria:
- Subjects with serious diseases including cancer, uncontrolled hypertension, diabetes mellitus requiring insulin injection, life-threatening cardiovascular or neurological events, chronic respiratory disease, a haemorrhagic disorder and serious mental diseases
- Subjects had pain in the knee may caused by inflammatory, malignant, autoimmune disease or traumatic injury;
- Subjects received knee replacement surgery for the affected knee
- Subjects received knee arthroscopy within the past year, steroid or hyaluronic acid injection in the knee joints within the previous 3 months
- Subject who currently participate in another clinical trial
- Subjects received physiotherapy or other treatments for osteoarthritis knee pain (with the exception of non-steroidal anti-inflammatory drugs) during the previous 4 weeks;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: real moxibustion plus placebo gel
In subjects with osteoarthritis of the knee
|
3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )
4 grams per knee, 4 times per day, for 4 weeks
|
Active Comparator: diclofenac sodium gel plus sham moxibustion
In subjects with osteoarthritis of the knee
|
4 grams per knee, 4 times per day, for 4 weeks
3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The change of the global scale of the Western Ontario and McMaster Osteoarthritis Index (WOMAC)
Time Frame: 4 weeks from baseline
|
4 weeks from baseline
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The changes from baseline to 2, 4, 8,12 weeks in the WOMAC subscales (pain, stiffness, and function)
Time Frame: at baseline(0 week), 2 weeks, 4weeks, 8 weeks and 12 weeks later after allocation
|
at baseline(0 week), 2 weeks, 4weeks, 8 weeks and 12 weeks later after allocation
|
The change from baseline to 2, 4, 8,12 weeks in Visual Analogue Scale for the pain intensity.
Time Frame: at baseline(0 week), 2 weeks, 4weeks, 8 weeks and 12 weeks later after allocation
|
at baseline(0 week), 2 weeks, 4weeks, 8 weeks and 12 weeks later after allocation
|
The change of Patient global assessment score
Time Frame: 2 weeks, 4weeks, 8 weeks and 12 weeks later after allocation
|
2 weeks, 4weeks, 8 weeks and 12 weeks later after allocation
|
Collaborators and Investigators
Investigators
- Study Director: Yong Tang, Professor, Chengdu University of Chinese Traditional Medicine
- Principal Investigator: Jianying Zhou, Chengdu University of Chinese Traditional Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Osteoarthritis, Knee
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Diclofenac
Other Study ID Numbers
- 2015CB55450401
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Knee Osteoarthritis
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Tianjin XinChen-Techfields Pharma Co., LTD.Completed
-
Eun Jung KimMinistry of Health & Welfare, Korea; Semyung UniversityUnknownOsteoarthritis KneeKorea, Republic of
-
Novartis PharmaceuticalsRecruitingSymptomatic Knee OsteoarthritisUnited States, Spain, Hungary, Argentina, Germany, Slovakia, Czechia, Belgium, Romania
-
University of BathUniversity of Oxford; 3D Metal Printing Ltd; Versus ArthritisRecruitingMedial Knee OsteoarthritisUnited Kingdom
Clinical Trials on real moxibustion
-
NYU Langone HealthColumbia UniversityCompletedHIV Infections | HIV | Peripheral Neuropathy | AIDSUnited States
-
New York UniversityNational Institutes of Health (NIH)RecruitingPain | HIV/AIDS | Neuropathic Pain | HIV NeuropathyUnited States
-
Shanghai Institute of Acupuncture, Moxibustion...Completed
-
New York UniversityNational Institutes of Health (NIH)UnknownIrritable Bowel SyndromeUnited States
-
National Center for Complementary and Integrative...CompletedHIV Infections | Peripheral NeuropathiesUnited States
-
Henan University of Traditional Chinese MedicineRecruitingAllergic RhinitisChina
-
Shanxi Acupuncture and Moxibustion HospitalXinghualing Hospital of Traditional Chinese Medicine, Taiyuan City, Shanxi... and other collaboratorsRecruiting
-
Shanghai Institute of Acupuncture, Moxibustion...Completed
-
Shanghai Institute of Acupuncture, Moxibustion...Completed
-
Guangzhou University of Chinese MedicineUnknownChronic Fatigue SyndromeChina